Podcasts

Drs Park and Beckermann discuss kidney cancer highlights from the 2026 Genitourinary Cancers Symposium.

Drs Matulonis and Esselen explore the growing effect of financial toxicity in gynecologic oncology, emphasizing how economic burden can influence access to care, treatment adherence, and patient outcomes.

Dr Leal discusses variability in community practice and evolving treatment strategies for patients with small cell lung cancer.

Drs Rotow and Dietrich discuss the significance of the accelerated FDA approval of zongertinib (Hernexeos) for patients with HER2 TKD–mutated NSCLC.

Dr Shields discusses the realities of treating patients with SCLC in the community setting and how emerging therapies are shaping care delivery.

Drs Marshall and Lieu discuss the clinical relevance of KRAS G12C and pan-RAS inhibitors in the management of pancreatic and colorectal cancers.

Drs Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm.

Marina Baretti, MD, discussed the potential utilization of tissue-free ctDNA monitoring for early recurrence detection and treatment monitoring in CCA.

Drs Armstrong and Tawagi spotlight the most practice-informing data to come out of the 2026 Genitourinary Cancers Symposium.

Jonathan Trent, MD, PhD, and Neeta Somaiah, MD, discuss the importance of identifying genomic drivers and resistance patterns for therapy selection in GIST.

Dr Vale discusses data from a phase 2 trial evaluating blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Drs Camidge and Reed chronicle Dr Reed’s experience-rich career, recognizing the motivations and people at each stop that made his success possible.

Drs Tiesi, Scholer, and Pletcher discuss the growing role for TAMP as a regional therapy strategy for patients with locally advanced PDAC.

Sonali Smith, MD, discusses CAR-T cell therapies moving into solid tumors, the role of clinical trials in hematologic oncology, and the rising incidence of certain cancers in young adults.

Drs McCann and Nunnery share their stories and perspectives as leading women in oncology in honor of International Women's Day.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of daratumumab plus VRd for the treatment of newly diagnosed, transplant-ineligible multiple myeloma.

Eric K. Singhi, MD, discusses where TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan may fit in evolving treatment algorithms in lung cancer.

Drs Camidge and Clackson discussed Dr Clackson’s career journey through the biotechnology field, which began with a curiosity about biology and evolution.

Anne Chiang, MD, PhD, discusses the rapidly evolving treatment landscape in SCLC and what this new era of innovation means for patients.